Skip to main content
Herriot Tabuteau, MD, Other MD/DO, New York, NY

HerriotTabuteauMD

Other MD/DO • New York, NY

Axsome Therapeutics, Inc.

Join to view full profile

Dr. Tabuteau is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Tabuteau's full profile

Already have an account?

Education & Training

  • Yale School of Medicine
    Yale School of MedicineClass of 1994

Publications & Presentations

PubMed

Press Mentions

  • Pharmanovia Enters in-Licensing Agreement with Axsome Therapeutics to Market and Further Develop Sunosi® (Solriamfetol), a First-in-Class Treatment for Excessive Daytime Sleepiness (EDS) in People with Narcolepsy and Obstructive Sleep Apnoea
    Pharmanovia Enters in-Licensing Agreement with Axsome Therapeutics to Market and Further Develop Sunosi® (Solriamfetol), a First-in-Class Treatment for Excessive Daytime Sleepiness (EDS) in People with Narcolepsy and Obstructive Sleep ApnoeaFebruary 21st, 2023
  • Axsome Therapeutics (Finally) Earns Approval. Here's What's Next
    Axsome Therapeutics (Finally) Earns Approval. Here's What's NextAugust 24th, 2022
  • Axsome Therapeutics Announces Publication of Pivotal ASCEND Phase 2 Trial of AXS-05 in Major Depressive Disorder in the American Journal of Psychiatry
    Axsome Therapeutics Announces Publication of Pivotal ASCEND Phase 2 Trial of AXS-05 in Major Depressive Disorder in the American Journal of PsychiatryMay 18th, 2022
  • Join now to see all

Dr. Herriot Tabuteau, Dr. Herriot Tabuteau, MD, Dr. H Tabuteau